Company: EVGN
Filing Date: 2025-06-17
Form Type: 6-K
Source: 0001178913-25-002196
Chunk: 0

Company: Evogene Ltd.
Filing Date: 2025-06-17
Form: 6-K
Chunk 0
---
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 17, 2025 Commission File Number: 001-36187 EVOGENE LTD. (Translation of Registrant’s Name into English) 13 Gad Feinstein Street, Park Rehovot Rehovot 7638517, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒Form 40-F ☐ CONTENTS Notice, Proxy Statement and Proxy Card for Annual General Meeting of Shareholders Evogene Ltd. (“ Evogene”) hereby publishes a notice of an annual general meeting of shareholders (the “ Meeting”), which is scheduled to take place at 3:00 p.m. (Israel time) on Monday, August 11, 2025, at Evogene’s offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel. Shareholders of record at the close of business on Monday, June 23, 2025, are entitled to vote at the Meeting. Attached as Exhibit 99.1 to this Report of Foreign Private Issuer on Form 6-K (this “ Form 6-K”) is the Notice of Annual General Meeting of Shareholders, which contains information concerning the agenda for the Meeting, the required majority for approval of each proposal at the Meeting, the voting procedure and additional general matters related to the Meeting. Attached as Exhibit 99.2 to this Form 6-K is the Proxy Statement for the Meeting, which describes in greater detail the proposals to be presented at the Meeting, including background information related to the proposals, additional logistical information concerning the required vote and means of voting on the proposals, and general information concerning Evogene’s board of directors and corporate governance. Attached as Exhibit 99.3 to this Form 6-K is the form of proxy card being distributed by Evogene to its shareholders of record as of the record date for the Meeting, which serves as the primary means for those shareholders to cast their votes on the proposals to be presented at the Meeting. The contents of Exhibits 99.1, 99.2 and 99.3 to this